Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Medicina (B.Aires) ; 81(1): 6-10, mar. 2021. graf
Article Dans Espagnol | LILACS | ID: biblio-1287234

Résumé

Resumen La fibrinólisis intravenosa con activador del plasminógeno tisular recombinante (rTPA) y la utilización de unidades cerradas, demostraron disminuir sustancialmente la morbimortalidad en pacientes con accidente cerebrovascular isquémico (ACVi). Sin embargo, los datos publicados en Argentina son escasos. Describimos la experiencia en la utilización de fibrinólisis en pacientes con ACVi agudo antes y después de la implementación de una unidad cerebrovascular (UCV) en un Centro Integral de Neurología Vascular de la Ciudad de Buenos Aires durante 17 años. Se realizó un análisis retrospectivo de pacientes consecutivos tratados con rTPA entre enero 2003 y diciembre 2019. Se evaluaron tiempos de tratamiento, de internación, complicaciones post tratamiento y discapacidad a 3 meses. Para su análisis se evaluaron los períodos pre y post apertura de la UCV, período 1 (P1 de 2003-2011) y P2 (2012 -2019). Se realizó fibrinolisis intravenosa en 182 pacientes. La apertura de UCV resultó en aumento del porcentaje de fibrinólisis sobre el total de los ACVi ingresados (4% en P1 vs. 10% en P2, p < 0.001), acortamiento del tiempo puerta-aguja (75 minutos en P1 vs. 53 minutos en P2, p < 0.00001) y mayor proporción de pacientes tratados dentro de los 60 minutos del ingreso hospitalario (36% en P1 vs. 76% en P2, p < 0.00001). Además, hubo reducción de la mediana de internación de 9 días en P1 a 5 días en P2 (p < 0.00001). En conclusión, la UCV parece optimizar la utilización de fibrinólisis en el ACVi agudo, aumentando el porcentaje de pacientes tratados, reduciendo el tiempo puerta-aguja y disminuyendo el de internación.


Abstract Intravenous fibrinolysis with recombinant tissue plasminogen activator (rTPA) and use of stroke units improve morbidity and mortality in patients with acute ischemic stroke (AIS). However, data published in Argentina are scarce. We describe the experience in the use of fibrinolysis in patients with acute ischemic stroke (AIS) before and after the implementation of a stroke unit in a Comprehensive Stroke Center in Buenos Aires during the last 17 years. Retrospective analysis of consecutive patients treated with rTPA between January 2003 and December 2019. Treatment times, hospitalization time, post-treatment complications and disability at 3 months were evaluated. For the analysis, the pre and post opening periods of the stroke unit were evaluated, Period 1 (P1, from 2003 to 2011) and Period 2 (P2, from 2012 to 2019). Intravenous fibrinolysis was performed in 182 patients. Opening of the stroke unit resulted in an increase in the percentage of fibrinolysis over the total number of admitted strokes (4% in P1 vs. 10% in P2, p < 0.001), shortening of the door-to-needle time (75 minutes in P1 vs. 53 minutes in P2, p < 0.00001) and higher proportion of patients treated within 60 minutes of hospital admission (36% in P1 vs. 76% in P2, p < 0.00001). In addition, there was a reduction in the median hospital stay from 9 days in P1 to 5 days in P2 (p < 0.00001). In conclusion, stroke units seem to optimize the use of fibrinolysis in acute stroke, increasing the percentage of patients treated, reducing door-to-needle time, and reducing hospitalization time.


Sujets)
Humains , Encéphalopathie ischémique/traitement médicamenteux , Accident vasculaire cérébral/traitement médicamenteux , Argentine , Traitement thrombolytique , Études rétrospectives , Résultat thérapeutique , Activateur tissulaire du plasminogène/usage thérapeutique , Fibrinolyse , Fibrinolytiques/usage thérapeutique
2.
Chinese Journal of Nervous and Mental Diseases ; (12): 720-723, 2015.
Article Dans Chinois | WPRIM | ID: wpr-670171

Résumé

Objetive To investigate physicians'knowledge regarding intravenous fibrinolytic therapy for acute ischemic stroke and whether their hospitals could meet the requirements for the therapy. Methods Questionnaires were mailed to 500 physicians from 153 hospitals in Shanxi including 112 secondary and 41 tertiary hospitals. 370 physicians returned valid questionnaires. Results One hundred thirty-four hospitals (87.6%) could provide 24-hour computed to?mography service, including 95 (84.8%) secondary hospitals and 39 (95.1%) tertiary hospitals. Alteplase stock was avail?able in 59 hospitals (38.6%), containing 25 (22.3%) secondary and 34 (82.9%) tertiary hospitals. Accuracy rates of 13 questions regarding intravenous fibrinolytic therapy for acute ischemic stroke ranged from 30.8% to 82.9%. Accuracy rates of 6 questions were lower than 50.0%. Conclusions The present study has revealed that physicians in this study have poor knowledge regarding the therapy. The situation can not meet the demand of healthcare, which partially ac?counts for the low rate in fibrinolytic therapy in Shanxi. Relevant training and suitable assessment should be carried out compulsively to ensure that physicians grasp necessary knowledge and skills.

SÉLECTION CITATIONS
Détails de la recherche